NVO is trading 3.2% up at $49.48 as Medicare’s GLP-1 Bridge program officially launches, significantly expanding insurance coverage for Novo Nordisk’s obesity drug Wegovy.
- Eligible beneficiaries can now access the weight-loss medication with a $50 monthly copay, marking the first large-scale Medicare coverage for this drug class.
- The program is viewed as a major commercial catalyst that broadens the potential patient pool and creates a substantial new revenue opportunity for the company.
- This expansion helps mitigate previous investor concerns regarding pricing pressure and market access for GLP-1 manufacturers.